Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000412631 | SCV001231156 | uncertain significance | Neuropathy, hereditary motor and sensory, type 6B | 2024-11-03 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 249 of the SLC25A46 protein (p.Gly249Asp). This variant is present in population databases (rs200725073, gnomAD 0.01%). This missense change has been observed in individual(s) with clinical features of SLC25A46-related conditions and/or optic atrophy and axonal peripheral neuropathy (PMID: 26168012, 33841295). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 372238). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt SLC25A46 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change does not substantially affect SLC25A46 function (PMID: 27543974). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002392936 | SCV002671346 | uncertain significance | Inborn genetic diseases | 2022-12-08 | criteria provided, single submitter | clinical testing | The c.746G>A (p.G249D) alteration is located in exon 8 (coding exon 8) of the SLC25A46 gene. This alteration results from a G to A substitution at nucleotide position 746, causing the glycine (G) at amino acid position 249 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
OMIM | RCV000412631 | SCV000490313 | pathogenic | Neuropathy, hereditary motor and sensory, type 6B | 2017-01-14 | no assertion criteria provided | literature only |